Your browser doesn't support javascript.
loading
Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
Croarkin, Paul E; Elmaadawi, Ahmed Z; Aaronson, Scott T; Schrodt, G Randolph; Holbert, Richard C; Verdoliva, Sarah; Heart, Karen L; Demitrack, Mark A; Strawn, Jeffrey R.
Afiliação
  • Croarkin PE; Division of Child and Adolescent Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic, Rochester, Minnesota, USA. croarkin.paul@mayo.edu.
  • Elmaadawi AZ; Beacon Health System, South Bend, Indiana USA, Indiana University School of Medicine, South Bend, USA.
  • Aaronson ST; Sheppard Pratt Health System, Baltimore, Maryland, USA.
  • Schrodt GR; Integrative Psychiatry, Louisville, Kentucky, USA.
  • Holbert RC; Shands Psychiatric Hospital, Gainesville, Florida, USA.
  • Verdoliva S; North American Science Associates, Inc. (NAMSA) Minneapolis, Minnesota, USA.
  • Heart KL; Neuronetics, Inc. Malvern, Pennsylvania, USA.
  • Demitrack MA; Trevena, Inc. Chesterbrook, Pennsylvania, USA.
  • Strawn JR; Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.
Neuropsychopharmacology ; 46(2): 462-469, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32919400
ABSTRACT
Treatment-resistant depression (TRD) is prevalent and associated with a substantial psychosocial burden and mortality. There are few prior studies of interventions for TRD in adolescents. This was the largest study to date examining the feasibility, safety, and efficacy of 10-Hz transcranial magnetic stimulation (TMS) for adolescents with TRD. Adolescents with TRD (aged 12-21 years) were enrolled in a randomized, sham-controlled trial of TMS across 13 sites. Treatment resistance was defined as an antidepressant treatment record level of 1 to 4 in a current episode of depression. Intention-to-treat patients (n = 103) included those randomly assigned to active NeuroStar TMS monotherapy (n = 48) or sham TMS (n = 55) for 30 daily treatments over 6 weeks. The primary outcome measure was change in the Hamilton Depression Rating Scale (HAM-D-24) score. After 6 weeks of blinded treatment, improvement in the least-squares mean (SE) HAM-D-24 scores were similar between the active (-11.1 [2.03]) and sham groups (-10.6 [2.00]; P = 0.8; difference [95% CI], - 0.5 [-4.2 to 3.3]). Response rates were 41.7% in the active group and 36.4% in the sham group (P = 0.6). Remission rates were 29.2% in the active group and 29.0% in the sham group (P = 0.95). There were no new tolerability or safety signals in adolescents. Although TMS treatment produced a clinically meaningful change in depressive symptom severity, this did not differ from sham treatment. Future studies should focus on strategies to reduce the placebo response and examine the optimal dosing of TMS for adolescents with TRD.
Texto completo: Disponível Coleções: Bases de dados internacionais Contexto em Saúde: Agenda de Saúde Sustentável para as Américas Tema em saúde: Objetivo 9: Redução de doenças não transmissíveis Base de dados: MEDLINE Tipo de estudo: Ensaio clínico controlado Idioma: Inglês Revista: Neuropsychopharmacology Assunto da revista: Neurologia / Psicofarmacologia Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: Estados Unidos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Contexto em Saúde: Agenda de Saúde Sustentável para as Américas Tema em saúde: Objetivo 9: Redução de doenças não transmissíveis Base de dados: MEDLINE Tipo de estudo: Ensaio clínico controlado Idioma: Inglês Revista: Neuropsychopharmacology Assunto da revista: Neurologia / Psicofarmacologia Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: Estados Unidos